Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "MTD"

4 News Found

MTD acquires Ypsomed's pen needle and BGM businesses
Equipment | April 01, 2024

MTD acquires Ypsomed's pen needle and BGM businesses

This acquisition enables MTD to open new, strategic markets

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug
Diagnostic Center | October 30, 2023

SN Bioscience announces Phase 1 study results of SN-38 nanoparticle anti-cancer drug

Impressive safety and efficacy for solid cancer patients followed by global clinical study plan

Indian Pharma Market witnesses rise in volumes and prices in September.
News | October 28, 2021

Indian Pharma Market witnesses rise in volumes and prices in September.

Acute therapies continue to report strong growth compared to chronic ones.

World’s first clinical trial for a rare headache disorder
Biotech | September 15, 2021

World’s first clinical trial for a rare headache disorder

The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022

Latest Stories

Cipla invests additional Rs. 26 crore in Achira

Granules India posts Q4 FY24 consolidated PAT at Rs. 129.64 Cr

Ind-Swift posts Q4 FY24 consolidated PAT at Rs. 37.53 Cr

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging